Nuformix plc Logo

Nuformix plc

NFX.L

(1.5)
Stock Price

0,16 GBp

-196.01% ROA

-13.6% ROE

-3.24x PER

Market Cap.

3.066.553,00 GBp

0% DER

0% Yield

0% NPM

Nuformix plc Stock Analysis

Nuformix plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Nuformix plc Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.41x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

3 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

4 Net Profit Growth

Throughout the last three years, this company has experienced consistent net profit growth, reflecting a robust financial performance and making it an attractive investment prospect.

5 ROE

The stock's ROE indicates a negative return (-16.96%) on shareholders' equity, suggesting poor financial performance.

6 ROA

The stock's ROA (-196.01%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Nuformix plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Nuformix plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

Nuformix plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Nuformix plc Revenue
Year Revenue Growth
2016 0
2017 15.000 100%
2018 610.000 97.54%
2019 535.000 -14.02%
2020 535.000 0%
2021 50.000 -970%
2022 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Nuformix plc Research and Development Expenses
Year Research and Development Expenses Growth
2016 0
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Nuformix plc General and Administrative Expenses
Year General and Administrative Expenses Growth
2016 685.057
2017 729.016 6.03%
2018 911.683 20.04%
2019 1.119.580 18.57%
2020 1.119.580 0%
2021 1.318.577 15.09%
2022 761.299 -73.2%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Nuformix plc EBITDA
Year EBITDA Growth
2016 -685.057
2017 -1.546.559 55.7%
2018 -1.614.003 4.18%
2019 -832.898 -93.78%
2020 -832.898 0%
2021 -1.233.296 32.47%
2022 -724.404 -70.25%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Nuformix plc Gross Profit
Year Gross Profit Growth
2016 0
2017 -188.868 100%
2018 72.473 360.6%
2019 201.405 64.02%
2020 201.405 0%
2021 48.305 -316.94%
2022 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Nuformix plc Net Profit
Year Net Profit Growth
2016 -685.057
2017 -1.838.263 62.73%
2018 -1.661.227 -10.66%
2019 -756.376 -119.63%
2020 -756.376 0%
2021 -1.108.993 31.8%
2022 -760.136 -45.89%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Nuformix plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2016 0
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Nuformix plc Free Cashflow
Year Free Cashflow Growth
2016 -496.318
2017 -1.632.560 69.6%
2018 -326.767 -399.61%
2019 -761.015 57.06%
2020 -190.254 -300%
2021 -1.345.667 85.86%
2022 -433.097 -210.71%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Nuformix plc Operating Cashflow
Year Operating Cashflow Growth
2016 -496.318
2017 -1.531.264 67.59%
2018 -299.342 -411.54%
2019 -717.812 58.3%
2020 -179.453 -300%
2021 -1.345.667 86.66%
2022 -433.097 -210.71%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Nuformix plc Capital Expenditure
Year Capital Expenditure Growth
2016 0
2017 101.296 100%
2018 27.425 -269.36%
2019 43.203 36.52%
2020 10.801 -300.03%
2021 0 0%
2022 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Nuformix plc Equity
Year Equity Growth
2015 502.340
2016 -179.592 379.71%
2017 4.493.142 104%
2018 3.815.330 -17.77%
2019 4.742.520 19.55%
2020 5.686.261 16.6%
2021 4.737.962 -20.01%
2022 4.228.204 -12.06%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Nuformix plc Assets
Year Assets Growth
2015 544.791
2016 19.622 -2676.43%
2017 5.027.139 99.61%
2018 4.634.849 -8.46%
2019 5.126.433 9.59%
2020 6.010.885 14.71%
2021 4.975.823 -20.8%
2022 4.501.759 -10.53%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Nuformix plc Liabilities
Year Liabilities Growth
2015 42.451
2016 199.214 78.69%
2017 533.997 62.69%
2018 819.519 34.84%
2019 383.913 -113.46%
2020 324.624 -18.26%
2021 237.861 -36.48%
2022 273.555 13.05%

Nuformix plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0
Price to Earning Ratio
-3.24x
Price To Sales Ratio
0x
POCF Ratio
-5.69
PFCF Ratio
-7.08
Price to Book Ratio
0.58
EV to Sales
0
EV Over EBITDA
-3.88
EV to Operating CashFlow
-6.48
EV to FreeCashFlow
-6.48
Earnings Yield
-0.31
FreeCashFlow Yield
-0.14
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.01
Graham NetNet
-0

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.57
ROE
-0.17
Return On Assets
-0.13
Return On Capital Employed
-0.15
Net Income per EBT
0.93
EBT Per Ebit
1
Ebit per Revenue
0
Effective Tax Rate
0.07

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.18
Return on Tangible Assets
-1.96
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,01
Tangible Book Value per Share
0
Shareholders Equity per Share
0.01
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.36
Current Ratio
1.42
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.91
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Nuformix plc Dividends
Year Dividends Growth

Nuformix plc Profile

About Nuformix plc

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.

CEO
Dr. Daniel John Gooding
Employee
3
Address
60 Gracechurch Street
London, EC3V 0HR

Nuformix plc Executives & BODs

Nuformix plc Executives & BODs
# Name Age
1 Mr. Benjamin Harber
Company Secretary
70
2 Dr. Joanne M. Holland
Consultant
70
3 Dr. Daniel John Gooding
Executive Director
70

Nuformix plc Competitors

N4 Pharma Plc Logo
N4 Pharma Plc

N4P.L

(1.0)
Bidstack Group Plc Logo
Bidstack Group Plc

BIDS.L

(1.0)
genedrive plc Logo
genedrive plc

GDR.L

(0.8)